Video Summary - The Hormone No One Treats in Women: Testosterone, Libido & What Your Doctor Misses

Key wellness & self-care / productivity takeaways (from the episode)

Testosterone is present and functional in women’s bodies (produced by the ovaries, with additional contributions from peripheral conversion and adrenal sources).
It supports multiple domains of sexual health, including:
- desire
- arousal / blood flow
- orgasm (and reducing sexual distress)
- brain pathways (including dopamine/nerve support and myelin support)
It may not reliably treat sexual pain in every case, though clinicians may use targeted approaches for certain pain conditions.

There are no FDA-approved testosterone products for women in the U.S., even though men have multiple options—highlighting a gender disparity in research, approval, and coverage.
Providers may overlook other biologic drivers of “not feeling like myself,” such as:
- thyroid issues
- metabolic dysfunction (e.g., insulin resistance)
- iron deficiency (ferritin)
- vitamin D
- vitamin B12 deficiency
The episode emphasizes that persistent misery, low drive, or sexual dysfunction isn’t a character flaw—often it’s under-investigated biology.

Start with a thorough history:
- “What do you mean by not feeling like yourself?”
- rule out other contributors first.
Use a low-bar decision approach:
- cheap (relative to many therapies)
- safe at physiologic female doses (with clinician monitoring)
- include a trial window (often referenced as about 4 months)
Recognize limits:
- Testosterone won’t fix relationship dysfunction or non–sex-related interpersonal problems—screen those in parallel.
Discuss safety/side-effect reality:
- delivery method matters (e.g., pellets can be hard to titrate down quickly)
- rapid dose jumps may increase adverse effects (including hair shedding via “shock to the system”).

Because women lack FDA-approved testosterone options, dosing can involve “bootstrap” methods that may be less precise.
Pellets are described as:
- higher and harder to reverse/titrate quickly
- potentially linked to unwanted effects (likened to a “sea level to Everest” physiological shock)
- not inherently evil, but requiring responsible prescribing and dosing.
Topical testosterone considerations discussed:
- hair-growth risk depends on proximity to hair follicles
- genital application (e.g., vulva/labia) may increase absorption and requires caution
- vulvar pain protocols may differ (e.g., lower-dose compounded options with estradiol for specific vulvar pain presentations)

GSM affects many structures (vagina/vulva, urethra, bladder, clitoris, etc.) and can contribute to:
- recurrent UTIs
- overactive bladder
- pain with sex
Treatment underuse is highlighted:
- even after diagnosis, many women don’t receive vaginal estrogen or recommended care.
OTC vs Rx nuance:
- DHEA (via vaginal prasterone products in some contexts) provides local androgen/estrogen precursors
- vaginal estrogen remains “bread and butter” for many GSM outcomes.
Practical guidance:
- with vaginal estrogen, tissue typically needs ~6–8 weeks to rebuild
- if stopped, symptoms often return as tissues revert to low-estrogen status
- avoid a “loading dose” approach when there’s risk of over-absorption or tissue “burning” in highly atrophic tissue.

Pelvic floor dysfunction and vaginismus are treated as medical/tissue-and-muscle issues—not something you can “relax away.”
Vibrators and sexual-tech supports are framed as legitimate tools:
- vibration + blood flow + nerve stimulation can help (when used safely and appropriately)
- “simple is better” for many people (fewer settings; easier, more consistent stimulation)
- for GSM or untreated atrophy, external-only options may be gentler (internal insertion may be painful).

The episode repeatedly stresses that sexual changes can be medication-related:

Birth control pills may reduce free testosterone via increased SHBG
SSRIs and other antidepressants can blunt desire and/or orgasm for many people
some BP meds and antipsychotics may contribute
anticholinergics (e.g., for overactive bladder) can dry/tamper physiology
GLP-1s:
- might improve sex for some men via metabolic/weight changes
- in women, effects may be mixed, potentially mediated through dopamine/reward pathways—so outcomes vary.

When someone says “I don’t feel like myself,” start with:
- story + symptoms timeline
- labs that catch common deficiencies/dysregulation (thyroid, A1C, fasting insulin, ferritin, B12, D, etc.)
- then consider targeted hormone or pelvic interventions when appropriate
The episode frames this as reclaiming quality of life and motivation—not just “fixing libido.”

Dr. Kelly Casperson (Kelly Casperson, MD) – urologist; podcast You Are Not Broken; author of You Are Not Broken and The Menopause Moment
- The New Perimenopause is discussed as the host’s book, not hers
Dr. Mary Claire Haver – host of Unpaused; OB/GYN; certified menopause practitioner; adjunct professor at University of Texas Medical Branch
Dr. Rebecca Glazer – research mentioned on testosterone pellets and breast cancer risk
Louise Newsom’s group – mentioned for findings related to estrogen/testosterone and antidepressant discontinuation
Rachel Rubin – mentioned for GSM-related work and Medicare analysis; research on clitoral adhesions
Dr. Anna Lee – co-author of GSM guidelines (patient-facing handout discussed)
ISSSWSH website – suggested resource for finding clinicians (sex med + hormones overlap)
Odyssey / Pod People – credited as part of Unpaused presentation (at end)
Mark Cuban Cost Plus Drugs – mentioned as a cost option for generic vaginal estradiol
Uresta – OTC product advertisement referenced during episode
Pura – sponsor advertisement referenced during episode
K18 – sponsor advertisement referenced during episode
Daily Look – sponsor advertisement referenced during episode